A pathology report can turn a worrying biopsy into a page full of unfamiliar medical terms. This skin cancer pathology guide explains what those terms usually mean, what they can tell you about a lesion, and why the next conversation with your doctor matters. A report is not something you need to interpret alone. It is a key part of deciding whether treatment is complete or whether further care is needed.

Skin cancer is common in Australia, but early assessment and appropriately planned treatment can make a profound difference. If you are waiting for a result, have received one you do not understand, or notice a changing spot after a previous biopsy, contact the clinic or GP who arranged your test. Every minute counts when a suspicious lesion needs follow-up.

What a skin cancer pathology report does

Pathology is the examination of tissue under a microscope. After a doctor removes all or part of a suspicious mole, lump, sore or patch of skin, the sample is sent to a pathology laboratory. A specialist doctor called a pathologist examines the cells and issues a written report.

The report helps confirm whether the lesion is benign, precancerous or cancerous. If cancer is present, it may identify the type, how deeply it has grown, whether it has concerning features and whether cancer cells reach the edges of the sample. These findings guide treatment, but they are considered alongside the physical examination, the location of the lesion, your medical history and, in some cases, imaging or lymph node assessment.

A pathology report may be reassuring, even if the lesion looked suspicious. Conversely, a small spot can have features that require prompt further treatment. Appearance alone cannot provide the whole answer, which is why a biopsy can be so valuable.

Skin cancer pathology guide: terms you may see

Reports vary between laboratories, so wording is not always identical. The section called the diagnosis, conclusion or final diagnosis usually gives the clearest answer. Other sections provide detail that helps your treating clinician plan next steps.

Benign means the lesion is not cancer. Examples include common moles, seborrhoeic keratoses and harmless cysts. Your doctor may still discuss monitoring if you have many atypical moles or a strong family history of melanoma.

In situ means abnormal or cancerous cells are limited to the top layer of skin and have not invaded deeper tissue. Melanoma in situ and squamous cell carcinoma in situ need treatment, but they are generally managed differently from invasive disease.

Invasive means cancer cells have grown beyond their original skin layer into deeper tissue. This does not automatically mean cancer has spread elsewhere. It does mean the pathology details become particularly important in planning treatment and follow-up.

Margins are the edges of the tissue removed. A clear, negative or uninvolved margin means no cancer cells were seen at that edge of the specimen. A positive, involved or close margin can mean cancer cells extend to, or are very near, an edge. Further excision may be recommended, but the decision depends on the cancer type, the exact margin, the body site and the original procedure.

Dysplasia describes abnormal cells. In a mole, mild, moderate or severe dysplasia may be reported. These terms can be unsettling, but they do not all mean melanoma. Ask your doctor whether the lesion was completely removed and whether monitoring or a further procedure is advised.

If the report identifies melanoma

Melanoma pathology is detailed because some features are linked to the chance of the cancer returning or spreading. One of the most significant measurements is the Breslow thickness, which records how deep an invasive melanoma has grown in millimetres. In general, thinner melanomas have a better outlook, especially when detected and treated early.

The report may also comment on ulceration, meaning the skin surface over the melanoma has broken down. Ulceration can affect staging and treatment discussions. Other details may include the melanoma subtype, whether the lesion appears to have developed in an existing mole, mitotic activity and the presence or absence of regression.

Do not try to calculate your stage from one line in a report. Melanoma staging may also depend on clinical examination, lymph node findings and, for selected people, a sentinel lymph node biopsy or scans. Your GP, dermatologist or surgical team can explain what applies to you.

Common melanoma subtypes include superficial spreading melanoma, nodular melanoma, lentigo maligna melanoma and acral lentiginous melanoma. The subtype can provide useful context, but it does not replace the other information in the report. Nodular melanoma, for example, may grow quickly and can appear as a raised, firm or bleeding lump rather than a classic changing flat mole.

If the report identifies non-melanoma skin cancer

Basal cell carcinoma, or BCC, is the most common skin cancer. It often grows slowly and rarely spreads to distant parts of the body, but it can cause significant local damage if ignored, especially on the nose, ears, eyelids or lips. A pathology report may describe a BCC as nodular, superficial, infiltrative, micronodular or morphoeic. Some patterns have less clearly defined edges and may need a different surgical approach.

Squamous cell carcinoma, or SCC, can arise from sun-damaged skin and sometimes from an actinic keratosis. Reports may describe the tumour as well, moderately or poorly differentiated. They may also identify depth of invasion, perineural invasion, where cancer cells are seen around or within a nerve, or invasion into deeper structures. These features can increase risk and may affect the urgency or extent of treatment.

Actinic keratoses are sun-damage lesions rather than invasive skin cancers. They can feel rough or scaly and are common on the face, scalp, ears, forearms and backs of hands. Treatment may be recommended because some can progress to SCC over time.

Why clear margins are not the whole story

It is natural to look straight for the word clear. Clear margins are encouraging, but they do not always mean the same follow-up for every person. A small, low-risk BCC fully removed from the trunk is different from an SCC on the ear, or a melanoma where the initial biopsy was designed to diagnose the lesion rather than provide the final treatment margin.

For melanoma, doctors commonly recommend a wider excision around the biopsy scar after diagnosis. The amount of normal-looking skin removed depends largely on the Breslow thickness and the location of the melanoma. This is planned treatment, not necessarily evidence that the first procedure failed.

Likewise, a positive margin does not tell you by itself how urgent the situation is. It does mean you need a clear plan from your treating clinician. Do not postpone that conversation because the wound appears to be healing well.

Questions to take to your appointment

Bring a copy of the pathology report if you have one, and ask for plain-language explanations. Useful questions include: What exactly was found? Was the lesion fully removed? Do I need a wider excision, another biopsy or referral to a specialist? What follow-up schedule is right for my skin cancer type and risk factors? Should my family members be more alert to changing spots?

Also tell your clinician if you have had previous skin cancers, take medicines that suppress the immune system, have a family history of melanoma, work outdoors or have noticed other changing lesions. These details may change the recommended follow-up plan.

When to seek review promptly

Contact your doctor promptly if you have received a cancer diagnosis and have not been told the next step, if a biopsy site is not healing as expected, or if a treated area develops a new lump, persistent crust, bleeding or colour change. A new or changing spot elsewhere on your skin also deserves assessment, particularly if it is growing, different from your other moles, itchy, painful or repeatedly bleeding.

People with skin of colour can develop skin cancer too, including in less sun-exposed areas such as the soles, palms, nails and mouth. Do not dismiss a persistent dark streak under a nail or a changing patch simply because it does not fit the usual image of sun-related skin cancer.

Your pathology report is one part of your care, not a verdict you need to carry alone. Ask questions, keep your follow-up appointments and arrange a professional skin check when something changes. Knowledge can save your life, especially when it leads to timely action.